We believe the results will pave the way for a longer use in maintenance and increased penetration. Therefore we increase our daratumumab (Darzalex) peak sales forecast in multiple myeloma to 40 billion Danish crowns from 35 billion crowns and raise our target price to 1,100 crowns (1,025).